Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 6/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23066451 | 0.73 | — | — | |
| SCHEMBL28018292 | 0.70 | TSHR (0.36) | L3MBTL1MAPTMAPK1TDP1TSHR | |
| SCHEMBL1521846 | 0.70 | LMNA (0.37) | L3MBTL1MAPTMAPK1TDP1TSHR | |
| SCHEMBL4621280 | 0.68 | ALDH1A1 (0.31) | MAPT | |
| SCHEMBL6029027 | 0.67 | CALM1 (0.44) | MAPTTSHRLMNACYP1A2MAOB | |
| Benzylphenylether SCHEMBL28687993 | 0.67 | CYP1A2 (0.53) | L3MBTL1MAPTLMNACYP1A2PTGS1 | |
| SCHEMBL11285381 | 0.65 | MAPT (0.50) | L3MBTL1MAPTMAPK1TDP1TSHR | |
| SCHEMBL6469379 | 0.65 | TSHR (0.52) | L3MBTL1MAPTMAPK1TDP1TSHR | |
| SCHEMBL7834430 | 0.64 | HTR1A (0.51) | L3MBTL1MAPTMAPK1TDP1LMNA | |
| SCHEMBL265584 | 0.64 | MAPK1 (0.70) | L3MBTL1MAPTMAPK1TDP1LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | claimed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | claimed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| EP-1838686-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | claimed |
| US-11739070-B2 | C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-08-29 | — | — | US | disclosed |
| EP-3740476-A1 | C5A RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| US-20200347029-A1 | C5A RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-11-05 | — | — | US | disclosed |
| CN-111615513-A | C5a receptor modulators | 爱杜西亚药品有限公司 | 2020-09-01 | — | — | CN | disclosed |
| US-10696677-B2 | Diaryl purine derivatives with improved bioavailability | RESEARCH TRIANGLE INSTITUTE (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190352305-A1 | DIARYL PURINE DERIVATIVES WITH IMPROVED BIOAVAILABILITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-11-21 | — | — | US | disclosed |
| WO-2019141803-A1 | C5A RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-07-25 | — | — | WO | disclosed |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2010-01-21 | — | — | US | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1838686-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006073363-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347029-A1 | C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | L3MBTL1 4376/4885MAPT 4529/4885MAPK1 2297/4885 |
| US-20100016321-A1 | DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATOR | NR1H2, NR1H3, NR1I2 | L3MBTL1 4525/4885MAPT 1882/4885MAPK1 983/4885 |
| US-10696677-B2 | Diaryl purine derivatives with improved bioavailability | CNR1, CNR2, GPR119 | L3MBTL1 3623/4885MAPT 3290/4885MAPK1 1660/4885 |
| US-20190352305-A1 | DIARYL PURINE DERIVATIVES WITH IMPROVED BIOAVAILABILITY | CNR1, CNR2, GPR119 | L3MBTL1 3623/4885MAPT 3290/4885MAPK1 1660/4885 |
| US-11739070-B2 | C5A receptor modulators | C5AR1, C3AR1, C5AR2 | L3MBTL1 4376/4885MAPT 4529/4885MAPK1 2297/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | L3MBTL1 4564/4885MAPT 1938/4885MAPK1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.